ISSUE: Deliberative processes are intended to improve the quality of recommendations and decision making by allowing for participatory decision making, drawing on different kinds of participants, at different points of a decision-making cycle based on a consideration of facts and values. The HTAi-ISPOR task force – in close collaboration with the wider HTA community – has developed guidance for a deliberative process from an HTA perspective and a minimum set of considerations on the use of deliberative processes in HTA. Don Husereau will moderate and provide an overview of issues encountered by the Joint Task Force. Steve Pearson will provide a perspective of what is required practically and Mary Schrandt, and Newell McElwee will describe perspectives of clinicians/HTA bodies, patients, and the life sciences sector.

OVERVIEW: HTA organizations continue to improve processes including engagement with stakeholders. However, most HTA processes are still consultative and very few truly engage stakeholders. Panelists will discuss whether and how HTA processes can evolve to be become more deliberative. They will reflect on guidance from the Task Force to discuss its practical implications? Key questions that will be addressed include: Can guidance for HTA be a step forward? What else is needed to facilitate better participation? What can we learn from other areas? This session will provide an overview of practical challenges faced by HTA bodies, patients, industry and the research community in developing and implementing truly participatory processes in HTA.